OnkoMatch Tumor Genotyping by GenPath has just been launched! This assay personalizes cancer by providing, from 1 specimen, a molecular profile across 68 mutations in 14 oncogenes. Many of these oncogenes have targeted therapies either approved or in clinical trials. OnkoMatch technology, based on SNaPshot, has been licensed exclusively from Mass General Hospital and recently written up in the Annals of Oncology.
In The News